about
Type 2 diabetes is associated with decreased PGC1α expression in epicardial adipose tissue of patients with coronary artery diseaseCauses of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT).[Aldosterone receptor antagonist use after myocardial infarction. Data from the REICIAM registry].Expression of Sterol Regulatory Element-Binding Proteins in epicardial adipose tissue in patients with coronary artery disease and diabetes mellitus: preliminary study.Expression of epicardial adipose tissue thermogenic genes in patients with reduced and preserved ejection fraction heart failure.Clinical and echocardiographic course in tako-tsubo cardiomyopathy: Long-term follow-up from a multicenter study.Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes.Immediate and Long-Term Results of Drug-Eluting Stents in Mammary Artery Grafts.Long-term prognosis of complete percutaneous coronary revascularisation in patients with diabetes with multivessel disease.Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2.Clinical impact of acute kidney injury on short- and long-term outcomes after transcatheter aortic valve implantation with the CoreValve prosthesis.Transcatheter aortic valve implantation in very elderly patients: immediate results and medium term follow-up.Role of Gut Microbiota on Cardio-Metabolic Parameters and Immunity in Coronary Artery Disease Patients with and without Type-2 Diabetes MellitusLeft ventricular assist device.Assessment of long-term cognitive impairment after off-pump coronary-artery bypass grafting and related risk factors.Incidence and clinical outcome of prosthesis-patient mismatch after transcatheter aortic valve implantation with the CoreValve prosthesis.Poor reproducibility of the oral glucose tolerance test in the diagnosis of diabetes during percutaneous coronary intervention.Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction.Percutaneous implantation of the CoreValve® self-expanding valve prosthesis in patients with severe aortic stenosis and porcelain aorta: medium-term follow-up.Benefits of Cardiac Rehabilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coronary Intervention.Clinical impact of drug-eluting stents in an unselected population of diabetic patients.The importance of genotype-phenotype correlation in the clinical management of Marfan syndrome.Influence of cardiac rehabilitation on natriuretic peptides.Persistence of secondary mitral regurgitation and response to cardiac resynchronization therapy.Fibrillin 2 is upregulated in the ascending aorta of patients with bicuspid aortic valve.[Role of serum leptin in the severity of coronary artery disease in patients with stable angina].Newly impaired glucose metabolism and prognosis after percutaneous revascularization.[Factors influencing mobilisation of endothelial progenitor cells and angiogenic cytokines after an extensive acute myocardial infarction].[Coronary disease extension determines mobilization of endothelial progenitor cells and cytokines after a first myocardial infarction with ST elevation].Hereditary patterns of bicuspid aortic valve in a hundred families.Prognostic value of body mass index in transcatheter aortic valve implantation: A "J"-shaped curve.Repercussion of functional mitral regurgitation on reverse remodelling in cardiac resynchronization therapy.Serum levels of interleukin-2 predict the recurrence of atrial fibrillation after pulmonary vein ablation.Complete percutaneous revascularization in Takayasu's disease.[Performance of glycated hemoglobin and a risk model for detection of unknown diabetes in coronary patients].Influence of preinfarction angina on the release kinetics of endothelial progenitor cells and cytokines during the week after infarction.Clinical impact of intravascular ultrasound guidance in drug-eluting stent implantation for unprotected left main coronary disease: pooled analysis at the patient-level of 4 registries.Comparison of paclitaxel and everolimus-eluting stents in ST-segment elevation myocardial infarction and influence of thrombectomy on outcomes. ESTROFA-IM study.Prevalence of comorbidities and the prognostic value of the PROFUND index in a hospital cardiology unit.Does angina the week before protect against first myocardial infarction in elderly patients?
P50
Q28597641-A92892E8-11E8-4B1D-B5D5-CF88A5CD7D8AQ33946772-927CC8B1-1188-4A88-BF0E-3B550C1CBDBCQ34021213-1824BF9F-A752-4444-BDB9-692C7200D211Q37725920-CFF54844-BFDF-46E7-A659-C434DD5DB980Q38639885-C64E9EAF-A72D-47F0-9AF0-503CFF9CA0D6Q39174092-148A8A4B-0E47-432E-91E9-4BBED3C3C95FQ39199676-2BF60B7C-9EDA-41BB-A245-393352DE9440Q40471048-51DB00E0-578B-4924-9197-47F6D109CBD7Q41060812-C763110F-7CFB-4462-AB57-76264E695D4FQ41671886-35BE24BA-C103-4647-B617-667798FDD3F3Q41750012-A4BD59CA-5886-4B53-9B8B-E3176CC52F58Q41791006-BEA73F77-ACC1-405E-AAD7-85996D1BF2ACQ42373443-BDD1067C-F85F-4486-8966-50B0AF8D82DEQ43940806-41351492-2CA9-4221-A2C1-35A1126151E4Q44403941-C39DB34D-9A60-4AFB-B599-DE6882B122AAQ45072322-7A1E0834-7823-4FC6-9DD7-E879553FF13BQ46114600-684F04E0-7826-49C5-9116-58C01D6033BBQ46458268-EAFCF0E5-82B0-4D8B-986D-91E6C6C67304Q46973241-7B0DA987-3937-4AE2-B354-A24BC9E931C6Q47270262-0CCF17E1-A466-4883-B540-49DB55F1BACEQ47778717-5504290C-558C-4008-8051-CC8D2F42D7EEQ48192119-EA355124-32B5-4ABB-BA6C-CB166D8E1854Q48818868-6B5A6759-D820-4084-9D2A-A87108BCAA8AQ48947169-098BFB2B-FD2B-4C51-A956-D55A79B3A3B0Q50228724-BD1A0F5C-192D-441D-9B54-51FDF67FAE85Q50239647-91DD85B3-0DF4-4AF9-8914-6997F61FC225Q50475746-480FC664-F91C-44A9-9C47-DF6E97CE2293Q50520173-07401D40-26F0-4D80-ACDD-02A7D4685F14Q50525332-4A49E88F-BD57-429E-9A08-72982E607B2AQ50853547-3EB3FCC5-B079-43EF-B156-2045BC22467AQ50952642-974E85DE-8044-4180-A38E-A0F4EEC6E30AQ50978044-3A0A42A8-863B-4012-AB2D-CFBFCB28297CQ51048258-A4B3217A-ED50-422B-A353-89EA074AFA38Q51253069-199C669C-CB51-4E53-B9BE-42692AC8B4D5Q51370826-16B317A3-F969-48BF-B529-4FCDE4B17F36Q51575571-E9D7E84B-8404-44C5-ABDA-9D888E12A149Q51747144-FDBD400C-9896-43E9-89E1-32D8B6E61A61Q53383301-896C138A-86F8-4185-A30E-964D7315CBE8Q54102723-A6113704-D883-4211-8053-030EA71DC915Q73344108-05F607D0-EDA0-4B49-A344-A54A9855573A
P50
description
researcher
@en
wetenschapper
@nl
name
M Jiménez-Navarro
@en
M Jiménez-Navarro
@nl
type
label
M Jiménez-Navarro
@en
M Jiménez-Navarro
@nl
prefLabel
M Jiménez-Navarro
@en
M Jiménez-Navarro
@nl
P106
P31
P496
0000-0002-6759-0514